Arcturus Therapeutics Holdings Inc (ARCT)

Currency in USD
7.37
-0.10(-1.34%)
Closed·
7.29-0.08(-1.09%)
·
ARCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.277.60
52 wk Range
5.8524.17
Key Statistics
Prev. Close
7.37
Open
7.44
Day's Range
7.27-7.6
52 wk Range
5.85-24.17
Volume
437.61K
Average Volume (3m)
721.64K
1-Year Change
-53.3544%
Book Value / Share
8.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.56
Upside
+355.30%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Arcturus Therapeutics Holdings Inc Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc SWOT Analysis


mRNA Trailblaze
Arcturus Therapeutics leads with self-amplifying mRNA technology, potentially revolutionizing vaccine efficacy and safety profiles in a competitive market
Financial Trajectory
Explore Arcturus' path to profitability, balancing strong liquidity with negative margins as it aims to capitalize on its innovative pipeline
Strategic Alliances
Delve into Arcturus' partnership with CSL Seqirus, offering billions in potential milestones and global market access for its vaccine candidates
Market Opportunities
Analyst targets range from $41 to $140, reflecting diverse views on Arcturus' potential in COVID-19, influenza, and emerging vaccine markets
Read full SWOT analysis

Arcturus Therapeutics Holdings Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.34 missed $3.21 forecast; revenue fell to $28M from $50M year-over-year
  • Stock dropped 4.28% post-earnings but recovered 2.43% in after-hours trading
  • Operating expenses reduced 43.7% YoY; company extends financial runway into 2028
  • Focus on mRNA therapeutics pipeline; cystic fibrosis interim data expected September 2025
  • 6 analysts revised earnings upwards; company rated 'FAIR' with 2.49 Financial Health Score
Last Updated: 2025-08-11, 05:38 p/m
Read Full Transcript

Compare ARCT to Peers and Sector

Metrics to compare
ARCT
Peers
Sector
Relationship
P/E Ratio
−3.1x−1.9x−0.6x
PEG Ratio
0.550.100.00
Price/Book
0.9x2.1x2.6x
Price / LTM Sales
2.1x119.6x3.4x
Upside (Analyst Target)
171.4%37.6%44.9%
Fair Value Upside
Unlock10.5%6.3%Unlock

Analyst Ratings

9 Buy
3 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.56
(+355.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Roth/MKM
Buy20.00+171.37%-New CoverageJan 23, 2026
Citi
Hold7.00-5.02%9.00MaintainJan 06, 2026
Citi
Hold9.00+22.12%12.00MaintainNov 12, 2025
H.C. Wainwright
Hold9.00+22.12%12.00MaintainNov 12, 2025
H.C. Wainwright
Hold12.00+62.82%-DowngradeOct 24, 2025

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-0.49 / 5.53
Revenue / Forecast
17.15M / 279.77M
EPS Revisions
Last 90 days

ARCT Income Statement

People Also Watch

3.840
ATAI
+2.13%
167.29
JAZZ
+1.70%
46.81
TWST
+13.98%
8.33
KYTX
+4.00%
8.170
CRMD
+5.28%

FAQ

What Is the Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Today?

The Arcturus Therapeutics Holdings Inc stock price today is 7.37

What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?

Arcturus Therapeutics Holdings Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?

The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."

What Is the Arcturus Therapeutics Holdings Inc Market Cap?

As of today, Arcturus Therapeutics Holdings Inc market cap is 209.41M.

What Is Arcturus Therapeutics Holdings Inc's Earnings Per Share (TTM)?

The Arcturus Therapeutics Holdings Inc EPS (TTM) is -2.46.

When Is the Next Arcturus Therapeutics Holdings Inc Earnings Date?

Arcturus Therapeutics Holdings Inc will release its next earnings report on Mar 02, 2026.

From a Technical Analysis Perspective, Is ARCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Arcturus Therapeutics Holdings Inc Stock Split?

Arcturus Therapeutics Holdings Inc has split 1 times.

How Many Employees Does Arcturus Therapeutics Holdings Inc Have?

Arcturus Therapeutics Holdings Inc has 175 employees.

What is the current trading status of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Feb 03, 2026, Arcturus Therapeutics Holdings Inc (ARCT) is trading at a price of 7.37, with a previous close of 7.37. The stock has fluctuated within a day range of 7.27 to 7.60, while its 52-week range spans from 5.85 to 24.17.

What Is Arcturus Therapeutics Holdings Inc (ARCT) Price Target According to Analysts?

The average 12-month price target for Arcturus Therapeutics Holdings Inc is USD33.56, with a high estimate of USD72 and a low estimate of USD7. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +355.30% Upside potential.

What Is the ARCT After Hours Price?

ARCT's last after hours stock price is 7.29, the stock has decreased by -0.08, or -1.09%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.